Bioxcel therapeutics reports positive overall survival results from single-arm, open-label phase 2 trial of bxcl701 in patients with small cell neuroendocrine prostate cancer

Median overall survival of 13.6 months with bxcl701 + keytruda ® ( pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (cpi) in late-line refractory patients in separate, phase 2 trial 1
BTAI Ratings Summary
BTAI Quant Ranking